Keysight Technologies, Inc. (NYSE: KEYS) today announced that AttoTude Inc., a provider of terahertz (THz) interconnect technology for AI and hyperscale data center applications, has adopted enhanced ...

Preclinical data demonstrate how Soley's proprietary drug discovery platform translates cell stress biology into first-in-class drug candidates ...

This battery-powered, 2.4-GHz ISM-band transceiver uses DSSS modulation to achieve a wireless communications range as great as 300 m.

ARV-102 reduced endolysosomal and neuroinflammatory biomarkers implicated in Parkinson’s disease and progressive supranuclear palsy –– ARV-102 ...

Keysight Technologies launched updates to its test solution designed to aid validation of next-generation electrical and ...

ImmunoBrain, a clinical-stage biopharmaceutical company developing novel immunotherapies for neurodegenerative diseases, today presented new data from the first clinical study in Alzheimer's disease ...

New Assay Expands INDIGO’s GPCR Portfolio and Supports Development of Next-Generation CNS-Related Therapeutics STATE ...

The MarketWatch News Department was not involved in the creation of this content. MONTREAL, March 19, 2026 /PRNewswire/ -- Congruence Therapeutics today announced that the first participant has been ...

IPN01203 data to be presented at coveted New Drugs on the Horizon program session, demonstrating early potential of this novel T cell activator ...

FormaTK Systems Ltd., a global developer and manufacturer of advanced aesthetic medical technologies, announces the introduction of FineMotion™, a dedicated 808 nm diode laser treatment technology ...

The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for refractory epilepsies; Ovid advancing plans to initiate a Phase 2 trial in ...

Researchers identify the hippocampus and microglia as the "tipping point" that determines if chronic pain leads to depression or resilience.